报价延迟最少15分钟:2026/10/01 14:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
130.65 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
5.33/7.27
|
|
企业价值
9.98B
|
| 资产负债 |
|
每股账面净值
20.51
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
2.71B
|
|
每股收益
22.45
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide. |
